loading
Schlusskurs vom Vortag:
$26.40
Offen:
$26.6
24-Stunden-Volumen:
74,719
Relative Volume:
0.07
Marktkapitalisierung:
$1.75B
Einnahmen:
$8.30M
Nettoeinkommen (Verlust:
$-150.22M
KGV:
-10.10
EPS:
-2.64
Netto-Cashflow:
$-122.93M
1W Leistung:
+2.99%
1M Leistung:
-7.60%
6M Leistung:
-29.63%
1J Leistung:
-5.36%
1-Tages-Spanne:
Value
$26.28
$26.67
1-Wochen-Bereich:
Value
$22.93
$26.78
52-Wochen-Spanne:
Value
$22.93
$53.18

Celldex Therapeutics Inc Stock (CLDX) Company Profile

Name
Firmenname
Celldex Therapeutics Inc
Name
Telefon
908-200-7500
Name
Adresse
53 FRONTAGE ROAD, HAMPTON
Name
Mitarbeiter
160
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
CLDX's Discussions on Twitter

Vergleichen Sie CLDX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
CLDX 26.57 1.75B 8.30M -150.22M -122.93M -2.64
VRTX 447.21 115.74B 10.63B -479.80M -1.35B 13.33
REGN 737.75 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 586.52 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.92 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.55 24.49B 3.30B -501.07M 1.03B 11.54

Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-10-07 Eingeleitet Citigroup Buy
2024-09-30 Eingeleitet Goldman Neutral
2024-09-27 Herabstufung Wolfe Research Outperform → Peer Perform
2024-06-18 Eingeleitet Stifel Buy
2024-06-11 Eingeleitet Wolfe Research Outperform
2023-12-20 Eingeleitet TD Cowen Outperform
2023-11-10 Hochstufung Wells Fargo Underweight → Equal Weight
2023-08-22 Eingeleitet Wells Fargo Underweight
2021-09-17 Eingeleitet Jefferies Buy
2021-09-10 Eingeleitet SVB Leerink Outperform
2021-07-22 Eingeleitet Guggenheim Buy
2020-02-21 Eingeleitet Cantor Fitzgerald Overweight
2017-08-01 Fortgesetzt H.C. Wainwright Buy
2016-11-07 Eingeleitet Aegis Capital Buy
2016-03-08 Herabstufung Jefferies Buy → Hold
2016-03-07 Herabstufung Guggenheim Buy → Neutral
2016-03-07 Herabstufung Leerink Partners Outperform → Mkt Perform
2016-03-07 Herabstufung Wedbush Outperform → Neutral
2016-03-01 Eingeleitet H.C. Wainwright Buy
2015-08-11 Bestätigt Brean Capital Buy
2015-08-11 Bestätigt Oppenheimer Outperform
2015-08-11 Bestätigt ROTH Capital Buy
2015-06-02 Bestätigt WBB Securities Strong Buy
2014-11-17 Bestätigt ROTH Capital Buy
2014-03-04 Bestätigt Oppenheimer Outperform
2013-07-08 Bestätigt Cantor Fitzgerald Buy
2013-03-08 Bestätigt Cantor Fitzgerald Buy
2013-02-26 Bestätigt Oppenheimer Outperform
2013-01-10 Bestätigt Cantor Fitzgerald Buy
2012-10-02 Bestätigt Oppenheimer Outperform
2012-09-14 Bestätigt Cantor Fitzgerald Buy
Alle ansehen

Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten

pulisher
Nov 20, 2024

Insider Spends US$308k Buying More Shares In Celldex Therapeutics - Simply Wall St

Nov 20, 2024
pulisher
Nov 20, 2024

Celldex Therapeutics (NASDAQ:CLDX) Given Buy Rating at HC Wainwright - MarketBeat

Nov 20, 2024
pulisher
Nov 20, 2024

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases - The Manila Times

Nov 20, 2024
pulisher
Nov 20, 2024

Celldex Launches Phase 1 Trial of Novel Dual-Action Inflammatory Disease Treatment | CLDX Stock News - StockTitan

Nov 20, 2024
pulisher
Nov 20, 2024

Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock - Benzinga

Nov 20, 2024
pulisher
Nov 19, 2024

Celldex Therapeutics Reports Q3 2024 Progress and Financials - TipRanks

Nov 19, 2024
pulisher
Nov 16, 2024

Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month LowWhat's Next? - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Celldex stock touches 52-week low at $24.41 amid market shifts - Investing.com Canada

Nov 15, 2024
pulisher
Nov 15, 2024

Steven Cohen's Strategic Reduction in Celldex Therapeutics Holdi - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Eventide Asset Management's Strategic Acquisition in Celldex The - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria treatment - Investing.com India

Nov 14, 2024
pulisher
Nov 13, 2024

Polar Capital Holdings Plc Reduces Stake in Celldex Therapeutics Inc - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Insider Buying: Celldex Therapeutics Inc (CLDX) President & CEO Acquires Shares - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Celldex Therapeutics (NASDAQ:CLDX) Trading 4.2% Higher Following Insider Buying Activity - Defense World

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC's Strategic Reduction in Celldex Therapeutics Inc Shares - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

Insider Buying: Celldex Therapeutics, Inc. (NASDAQ:CLDX) CEO Buys 11,500 Shares of Stock - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Celldex Therapeutics CEO Anthony Marucci buys $308,430 in stock By Investing.com - Investing.com UK

Nov 12, 2024
pulisher
Nov 11, 2024

Celldex Therapeutics to Present at Upcoming Investor Conferences - The Manila Times

Nov 11, 2024
pulisher
Nov 11, 2024

Celldex (CLDX) to Present at Two Major Healthcare Investor Conferences in Q4 | CLDX Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 11, 2024

Leerink Partnrs Analysts Lower Earnings Estimates for CLDX - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

What is HC Wainwright's Estimate for CLDX FY2024 Earnings? - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

HC Wainwright Reiterates “Buy” Rating for Celldex Therapeutics (NASDAQ:CLDX) - Defense World

Nov 11, 2024
pulisher
Nov 08, 2024

Wellington Management Group LLP's Strategic Acquisition in Celld - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

FY2028 Earnings Forecast for CLDX Issued By Leerink Partnrs - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Celldex Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Nov 08, 2024
pulisher
Nov 08, 2024

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Nov 08, 2024
pulisher
Nov 06, 2024

Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 06, 2024
pulisher
Nov 06, 2024

Celldex: Q3 Earnings Snapshot - San Antonio Express-News

Nov 06, 2024
pulisher
Nov 06, 2024

Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

Celldex Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 06, 2024
pulisher
Nov 05, 2024

Celldex stock touches 52-week low at $25.04 amid market shifts By Investing.com - Investing.com South Africa

Nov 05, 2024
pulisher
Nov 05, 2024

Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month LowTime to Sell? - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Celldex stock touches 52-week low at $25.04 amid market shifts - Investing.com India

Nov 05, 2024
pulisher
Nov 04, 2024

Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market - Seeking Alpha

Nov 04, 2024
pulisher
Nov 04, 2024

Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire

Nov 04, 2024
pulisher
Nov 04, 2024

Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.

Nov 04, 2024
pulisher
Nov 03, 2024

Emerald Advisers LLC Has $15.51 Million Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat

Nov 03, 2024
pulisher
Oct 31, 2024

Evommune raises $115M to accelerate immune drug tests - Yahoo Finance

Oct 31, 2024
pulisher
Oct 29, 2024

Market reaction to Intellia data suggests perfection remains bar for gene editing - BioCentury

Oct 29, 2024
pulisher
Oct 29, 2024

Celldex Therapeutics (NASDAQ:CLDX) Trading Down 6%What's Next? - MarketBeat

Oct 29, 2024
pulisher
Oct 29, 2024

Prurigo Nodularis Pipeline Update 2024: FDA Approvals, - openPR

Oct 29, 2024
pulisher
Oct 29, 2024

Celldex shares hold as analyst maintains Buy rating By Investing.com - Investing.com UK

Oct 29, 2024
pulisher
Oct 29, 2024

Celldex selloff creates buying opportunity, says Guggenheim - Yahoo Finance

Oct 29, 2024
pulisher
Oct 28, 2024

Celldex shares gain as TD Cowen affirms Buy rating on robust Ph2 data - Investing.com UK

Oct 28, 2024
pulisher
Oct 28, 2024

Analyst Expectations For Celldex Therapeutics's Future - Benzinga

Oct 28, 2024
pulisher
Oct 28, 2024

HC Wainwright Reaffirms "Buy" Rating for Celldex Therapeutics (NASDAQ:CLDX) - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria - Investing.com India

Oct 28, 2024
pulisher
Oct 28, 2024

Celldex Therapeutics (NASDAQ:CLDX) pulls back 6.1% this week, but still delivers shareholders fantastic 57% CAGR over 5 years - Yahoo Finance

Oct 28, 2024
pulisher
Oct 27, 2024

Novo Holdings A S Grows Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat

Oct 27, 2024
pulisher
Oct 26, 2024

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria - ForexTV.com

Oct 26, 2024

Finanzdaten der Celldex Therapeutics Inc-Aktie (CLDX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):